Theranova dialyse improves clearance of toxins by hemodiafiltration.- Baxter International

Baxter International Inc., a leading provider of dialysis therapies, previewed Theranova a new class of dialysers with the potential to significantly advance renal care, at the 53rd Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA).

In data being presented at the Congress , the permeability and selectivity properties of the Theranova membrane demonstrated significantly higher mean overall toxin clearance compared to the currently marketed high-flux dialysers (Abstract #SP416). In vitro studies show that the Theranova dialyser delivers clearances of large uremic toxins (such as �-2 microglobulin) that are equivalent to and may exceed those of a hemodiafilter used in high-volume hemodiafiltration (HDF) mode. HDF is a dialysis therapy that also targets larger molecules.

Another Baxter study found that performing HD with the Theranova MCO HD removed middle molecules more efficiently with moderate albumin (common protein) loss in comparison to high-flux and haemodiafiltration (HDF) HD, suggesting treatment with Theranova MCO dialysers may provide clinical outcomes for patients that are similar to HDF (Abstract MP464) but at a lower cost.

Comment: Baxter has completed regulatory clearance for Theranova in Europe (CE marking), Australia and New Zealand , among other countries. It will be available in select countries in 2016, with additional launches planned for 2017. Theranova is not currently available in the United States.